Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer

International Journal of Oncology

Volumn 28, Issue 2, 2006, Pages 375-381

  Urano, Naomi ^a   Fujiwara, Yoshiyuki ^a   Doki, Yuichiro ^a   Kim, S J ^a   Miyoshi, Yasuo ^a   Noguchi, Shinzaburo ^a   Miyata, Hiroshi ^a   Takiguchi, Shuji ^a   Yasuda, Takushi ^a   Yano, Masahiko ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Class III tubulin; Docetaxel resistance; Gastric cancer; p53 gene mutation

Indexed keywords

ANTINEOPLASTIC AGENT; BETA III TUBULIN PROTEIN, HUMAN; BETA III-TUBULIN PROTEIN, HUMAN; DOCETAXEL; TAXOID; TUBULIN;

ADULT; AGED; ARTICLE; BIOPSY; BIOSYNTHESIS; DRUG COMBINATION; DRUG RESISTANCE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; STOMACH TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOPSY; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; TUBULIN;

EID: 33746851344     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.2.375     Document Type: Article

References (35)

1. Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
2. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997.
3. Roth AD, Maibach R, Martinelli G, et al: Docetaxel (Taxotere)- cisplatin(TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11: 301-306, 2000.
4. Roth AD and Ajani J: Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 14: 241-244, 2003.
5. Atsushi O: Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8: 95-102, 2005.
6. Parness J and Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 91: 479-487, 1981.
7. Horwitz SB, Cohen D and Rao S: Taxol: mechanism of action and resistance. Monogr J Natl Cancer Inst 5: 55-61, 1993.
8. Milross CG, Mason KA, Hunter NR, Chung YK, Peters LJ and Milas L: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88: 1308-1314, 1996.
9. Long BH and Fairchild C.R: Paclitaxel inhibits progression of mitotic cell to G phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res 54: 4355-4361, 1994.
10. Banerjee A: Increased levels of tyrosinated alpha-, beta (III)- and beta (IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun 293: 598-601, 2002.
11. Lewis A, Lee G and Cowan J: Five mouse tubulin isotypes and regulated expression during development. J Cell Biol 101: 852-861, 1985.
12. Jirasek T, Mandys V and Viklicky V: Expression of class III β-tubulin in neuroendocrine tumors of gastrointestinal tract. Folia Histochem Cytobiol 40: 305-310, 2002.
13. Carles G, Braguer D, Dumontet C, et al: Differentiation of human colon cancer cells changes the expression of β-tubulin isotypes and MAPs. Br J Cancer 80: 1162-1168, 1999.
14. Carles D, Sylvic I, Pierre-JS, et al: Expression of class III β-tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92: 25-30, 2005.
15. Kavallaris M, Kuo DYS, Burkhart CA, et al: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 100: 1282-1293, 1997.
16. Kavallaris M, Burkhart CA and Horwitz SB: Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80: 1020-1025, 1999.
17. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD and Hudes GR: Increase of III- and IVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56: 2584-2589, 1996.
18. Ranganathan S, Dexter DW, Benetatos CA and Hudes GR: Cloning and sequencing of human III-tubulin cDNA: induction of III isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta 1395: 237-245, 1998.
19. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR: Altered -tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562-566, 1998.
20. Hasegawa S, Miyoshi Y, Egawa C, et al: Prediction of response to docetaxel by quantitative analysis of class I and III β-tubulin isotype mRNA expression in human breast cancers 9: 2992-2997, 2003.
21. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
22. Ricky J, Astrid R and Scott L: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.
23. Fouret P, Temam S, Charlotte F and Lacau J: Tumor stage, node stage, p53 gene status and bcl-2 protein expression as predictors of tumor response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br J Cancer 87: 1390-1395, 2002.
24. Alnuld C, Helene B, Isabelle de W, et al: P53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol 18: 1465-1473, 2000.
25. Makatovskiy AN, Siryaporn E, Hixson DC and Akerley W: Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59: 1198-1211, 2002.
26. Bin L, Edger DS, Takeshi I, Hubert EA and John MH: Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 99: 179-186, 2001.
27. Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y and Noguchi S: Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 95: 255-259, 2001.
28. Achiwa H, Sato S, Shimizu S, et al: Analysis of β-tubulin gene alteration in human lung cancer cell lines. Cancer Lett 1: 211-216, 2003.
29. Sale S, Sung R, Shen P, et al: Conservation of the class I β-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther 1: 215-225, 2002.
30. Maeno K, Ito K, Hama Y, et al: Mutation of the class I β-tubulin gene dose not predict response to paclitaxel for breast cancer. Cancer Lett 30: 89-97, 2003.
31. Urano N, Fujiwara Y, Hasegawa S, et al: Absence of beta-tubulin gene mutation in gastric carcinoma. Gastric Cancer 6: 108-112, 2003.
32. Dulal P, Herbert PM, Asok B, Richard FL and Leslie W: Microtubules dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 91: 11358-11362, 1994.
33. Khan IA and Luduena RF: Phosphorylation of βII-tubulin. Biochemistry 35: 3704-3711, 1996.
34. Parker WB and Cheng YC: Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48: 381-395, 1990.
35. Deborah BZ and Stephen JL: Cisplatin and DNA repair in cancer chemotherapy. TIBS 20: 435-439, 1995.